Glenza 160mg

The Glenza 160mg tablet contains Enzalutamide as its active ingredient. This antineoplastic medication falls under the category of androgen receptor inhibitors. It is prescribed for the treatment of advanced prostate cancer in patients who have not responded to surgical or hormonal therapies.

If you are allergic to any of the components of this capsule, it is advised not to take it. Throughout the treatment, your physician may conduct periodic Prostate-specific antigen (PSA) tests. This blood test assesses the PSA level, a protein produced by the prostate gland that may be elevated in men diagnosed with prostate cancer. Monitoring PSA levels can provide insights into the disease’s progression and the effectiveness of the treatment. Additional tests may include liver function assessments and a complete blood count (CBC) to avert serious complications.

This medication has the potential to induce seizures; therefore, individuals with a history of seizures should exercise caution when using it. It is important to avoid grapefruit and grapefruit juice while on this medication, as they can elevate the drug’s levels in the body. This drug is contraindicated during pregnancy due to its potential harm to the unborn child, and it may also lead to fertility issues. Inform your doctor of any fertility concerns prior to commencing treatment with this medication. Before starting this treatment, it is crucial to notify your healthcare provider if you are pregnant or planning to conceive. Both men and women are advised to adhere to effective contraceptive methods during treatment and for three months following the final dose of Glenza 160mg tablet.